About: Bemcentinib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.

Property	Value
dbo:abstract	Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics. (en)
dbo:casNumber	1037624-75-1
dbo:fdaUniiCode	0ICW2LX8AS
dbo:kegg	D11438
dbo:pubchem	46215462
dbo:thumbnail	wiki-commons:Special:FilePath/Bemcentinib.svg?width=300
dbo:wikiPageID	56244890 (xsd:integer)
dbo:wikiPageLength	5327 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1047963363 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Enzyme_inhibitor dbc:Pyrrolidines dbc:Triazoles dbr:Melanoma dbr:Small_molecule dbr:Myelodysplastic_syndrome dbc:Experimental_cancer_drugs dbr:Triple-negative_breast_cancer dbr:COVID-19 dbr:Acute_myeloid_leukemia dbr:AXL_receptor_tyrosine_kinase dbc:Protein_kinase_inhibitors dbr:Non-small-cell_lung_cancer dbr:Phase_II_clinical_trial dbr:Metastatic_pancreatic_cancer
dbp:c	30 (xsd:integer)
dbp:casNumber	1037624 (xsd:integer)
dbp:h	34 (xsd:integer)
dbp:iupacName	1 (xsd:integer)
dbp:kegg	D11438 (en)
dbp:legalStatus	Investigational (en)
dbp:n	8 (xsd:integer)
dbp:pubchem	46215462 (xsd:integer)
dbp:smiles	Nc1ncnn1-c1cc2c-c1ccccc1CCC2 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	KXMZDGSRSGHMMK-RUZDIDTESA-N (en)
dbp:synonyms	BGB324; R428 (en)
dbp:unii	0 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist
dcterms:subject	dbc:Pyrrolidines dbc:Triazoles dbc:Experimental_cancer_drugs dbc:Protein_kinase_inhibitors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics. (en)
rdfs:label	Bemcentinib (en)
owl:sameAs	wikidata:Bemcentinib https://global.dbpedia.org/id/2YVp8
prov:wasDerivedFrom	wikipedia-en:Bemcentinib?oldid=1047963363&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Bemcentinib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Bemcentinib
is dbo:wikiPageRedirects of	dbr:Bemcentinib_(BGB324) dbr:C30H34N8 dbr:BGB324
is dbo:wikiPageWikiLink of	dbr:Bemcentinib_(BGB324) dbr:C30H34N8 dbr:AXL_receptor_tyrosine_kinase dbr:BGB324
is foaf:primaryTopic of	wikipedia-en:Bemcentinib